Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bone morphogenetic protein 7 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | 0.03 mg/ml BMP-7, single intraarticular knee injection |
| Arm 2 | ACTIVE_COMPARATOR | 0.1 mg/ml BMP-7, single intraarticular knee injection |
| Arm 3 | ACTIVE_COMPARATOR | 0.3 mg/ml BMP-7, single intraarticular knee injection |
| Arm 4 | PLACEBO_COMPARATOR | 1 ml placebo, single intraarticular knee injection (control) |
| Cohort 1 | EXPERIMENTAL | 0.03 mg/ml BMP-7 or placebo via intraarticular knee injection |
| Cohort 2 | EXPERIMENTAL | 0.1 mg/ml BMP-7 or placebo via intraarticular knee injection |
| Cohort 3 | EXPERIMENTAL | 0.3 mg/ml BMP-7 or placebo via intraarticular knee injection |
| Name | Type | Description |
|---|---|---|
| Bone morphogenetic protein 7 | DRUG | Comparison of different doses of the drug via single intraarticular knee injection |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Ambulatory with a diagnosis of OA of the knee with symptoms for at least 6 months and pain on the majority of days in the last 30 days. Symptoms must include knee joint pain. * A male or female adult age \>40 years * female subjects of childbearing potential must have a negati...